Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacogenetics Clear all
Completed Phase 3 Interventional Results available

Pharmacogenetics of Nicotine Addiction Treatment

NCT01314001
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Varenicline, Placebo, Transdermal Nicotine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

NCT00398645
View directory record Official record
Conditions
Asthma
Interventions
GW685698X 200mcg,GW685698X 200mcg and 400mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Fullerton, California • Huntington Beach, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

NCT00993200
View directory record Official record
Conditions
Blood Clotting
Interventions
warfarin pharmacogenetic dosing, Warfarin
Genetic · Drug
Lead sponsor
Robert Pendleton
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 21, 2026, 10:35 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to Sitagliptin (PRS)

NCT06813014
View directory record Official record
Conditions
Diabetes
Interventions
Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Not listed No phase listed Observational

Personalized Prediction of Tolerance and Immunogenicity in Hemophilia

NCT01626105
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
Victor J Marder, M.D.
Other
Eligibility
2 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 21, 2026, 10:35 PM EDT
Recruiting No phase listed Observational

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

NCT01441089
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

NCT02411123
View directory record Official record
Conditions
Depression, Anxiety
Interventions
IDgenetix Neuropsychiatric Test Panel
Genetic
Lead sponsor
AltheaDx
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Genetically Guided Statin Therapy

NCT01894230
View directory record Official record
Conditions
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions
SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Travis Air Force Base, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation

NCT00352547
View directory record Official record
Conditions
Renal Transplant
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Withdrawn Phase 2 Interventional

Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)

NCT00641511
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD)
Interventions
SYN117 (nepicastat), Placebo comparator
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Tuscaloosa, Alabama • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

NCT02508116
View directory record Official record
Conditions
Acute Coronary Syndrome, Cardiovascular Diseases
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational Results available

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

NCT01632267
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Not listed
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional Results available

Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

NCT04630093
View directory record Official record
Conditions
Pharmacogenetic Testing
Interventions
Panel-based pharmacogenetic genotyping
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional

Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States

NCT00054743
View directory record Official record
Conditions
HIV Infection
Interventions
Blood draw
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Naltrexone for Stimulant Abuse

NCT03226223
View directory record Official record
Conditions
Substance Use Disorders, Methamphetamine Abuse
Interventions
Intranasal Methamphetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)

NCT00187668
View directory record Official record
Conditions
Focus Groups
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 10:35 PM EDT
Completed No phase listed Observational

Role of Gene Variation in Effectiveness of Gleevec Treatment

NCT00342056
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional

Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

NCT00433953
View directory record Official record
Conditions
Kidney Transplant
Interventions
Mycophenolate Mofetil (CellCept), Dietary Monitoring, Drug Diary, Blood Sampling
Drug · Behavioral · Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 10:35 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism

NCT00330434
View directory record Official record
Conditions
Alcohol Drinking, Depression, Smoking Cessation, Attention Deficit Disorder
Interventions
Trial Withdrawn 1, Trial Withdrawn 2
Other
Lead sponsor
Tufts University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Genetics of the Acute Response to Alcohol in Social Drinkers

NCT01375556
View directory record Official record
Conditions
Alcoholism, Genetics
Interventions
Ethanol
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 30 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327
View directory record Official record
Conditions
Schizophrenia, Memory Disorders, Cognition Disorders
Interventions
Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing, Placebo
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 21, 2026, 10:35 PM EDT